Sondhi, Dolan

Publications

Sort by

Co-Author Network

selected publications

Identification of Safe and Effective Intravenous Dose of AAVrh.10hFXN to Treat the Cardiac Manifestations of Friedreich's Ataxia. Human gene therapy. 2023 Academic Article GET IT
Assessment of Residual Full-Length SV40 Large T Antigen in Clinical-grade Adeno-associated Virus Vectors Produced in 293T Cells. Human gene therapy. 2023 Academic Article GET IT
Safety of Intravenous Administration of an AAV8 Vector Coding for an Oxidation-Resistant Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency. Human gene therapy. 2023 Academic Article GET IT
Long-term functional correction of cystathionine β-synthase deficiency in mice by adeno-associated viral gene therapy. Journal of inherited metabolic disease. 2021 Academic Article GET IT
Automated Retinal Layer Segmentation in CLN2-Associated Disease: Commercially Available Software Characterizing a Progressive Maculopathy. Translational vision science & technology. 2021 Academic Article GET IT
Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy. Human gene therapy. 2021 Academic Article GET IT
Times cited: 12
Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Science translational medicine. 2020 Academic Article GET IT
Times cited: 27
Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates. Human gene therapy. 2020 Academic Article GET IT
Times cited: 14
Cocaine vaccine dAd5GNE protects against moderate daily and high-dose "binge" cocaine use. PloS one. 2020 Academic Article GET IT
Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich's Ataxia Corrected by AAV-mediated Gene Therapy. Human gene therapy. 2020 Academic Article GET IT
Times cited: 3
Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy. Human gene therapy. 2019 Academic Article GET IT
Times cited: 5
Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema. Allergy. 2019 Academic Article GET IT
Times cited: 30
Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease). Scientific reports. 2018 Academic Article GET IT
Times cited: 14
Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. The Lancet. Child & adolescent health. 2018 Academic Article GET IT
Times cited: 74
In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example. Human gene therapy methods. 2018 Academic Article GET IT
Times cited: 9
Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2. Experimental neurology. 2018 Academic Article GET IT
Times cited: 10
AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. Human gene therapy. Clinical development. 2018 Academic Article GET IT
Times cited: 70
Radioiodinated Capsids Facilitate In Vivo Non-Invasive Tracking of Adeno-Associated Gene Transfer Vectors. Scientific reports. 2017 Academic Article GET IT
Times cited: 13
Genetic Modification of the Lung Directed Toward Treatment of Human Disease. Human gene therapy. 2017 Review GET IT
Times cited: 23
Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2016 Academic Article GET IT
Times cited: 46
Gene therapy for metachromatic leukodystrophy. Journal of neuroscience research. 2016 Review GET IT
Times cited: 52
Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma. PloS one. 2016 Academic Article GET IT
Times cited: 18
Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. The Journal of allergy and clinical immunology. 2016 Academic Article GET IT
Times cited: 18
Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiology of aging. 2016 Academic Article GET IT
Times cited: 31
Brain Region-Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease). AJNR. American journal of neuroradiology. 2016 Academic Article GET IT
Times cited: 18
Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. Human gene therapy. Clinical development. 2015 Academic Article GET IT
Times cited: 51
Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer gene therapy. 2014 Academic Article GET IT
Times cited: 16
Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption. Journal of controlled release : official journal of the Controlled Release Society. 2014 Academic Article GET IT
Times cited: 64
Phase I/II study of intrapleural administration of a serotype rh.10 replication-deficient adeno-associated virus gene transfer vector expressing the human α1-antitrypsin cDNA to individuals with α1-antitrypsin deficiency. Human gene therapy. Clinical development. 2014 Academic Article GET IT
Times cited: 15
Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates. Human gene therapy. Clinical development. 2014 Academic Article GET IT
Times cited: 45
Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. Human gene therapy. 2014 Academic Article GET IT
Times cited: 34
Intrapleural administration of an AAVrh.10 vector coding for human α1-antitrypsin for the treatment of α1-antitrypsin deficiency. Human gene therapy. Clinical development. 2013 Academic Article GET IT
Times cited: 39
Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. Human molecular genetics. 2013 Academic Article GET IT
Times cited: 105
Cannulation of the internal carotid artery in mice: a novel technique for intra-arterial delivery of therapeutics. Journal of neuroscience methods. 2013 Academic Article GET IT
Times cited: 8
Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease. Human gene therapy. 2013 Review GET IT
Times cited: 19
Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function. PloS one. 2013 Academic Article GET IT
Times cited: 32
Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats. Human gene therapy. Clinical development. 2013 Academic Article GET IT
Times cited: 9
Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. Human gene therapy. 2012 Academic Article GET IT
Times cited: 20
Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Human gene therapy methods. 2012 Academic Article GET IT
Times cited: 75
Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging. AJNR. American journal of neuroradiology. 2012 Academic Article GET IT
Times cited: 16
Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Human gene therapy. 2012 Academic Article GET IT
Times cited: 69
Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements. Molecular therapy : the journal of the American Society of Gene Therapy. 2012 Academic Article GET IT
Times cited: 2
When ethics constrains clinical research: trial design of control arms in "greater than minimal risk" pediatric trials. Human gene therapy. 2011 Academic Article GET IT
Times cited: 10
Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. Journal of neurosurgery. Pediatrics. 2010 Academic Article GET IT
Times cited: 56
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Human gene therapy. 2008 Academic Article GET IT
Times cited: 300
Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Experimental neurology. 2008 Academic Article GET IT
Times cited: 58
Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology. 2007 Academic Article GET IT
Times cited: 71
Assessing disease severity in late infantile neuronal ceroid lipofuscinosis using quantitative MR diffusion-weighted imaging. AJNR. American journal of neuroradiology. 2007 Academic Article GET IT
Times cited: 25
Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Molecular therapy : the journal of the American Society of Gene Therapy. 2006 Academic Article GET IT
Times cited: 129
Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006 Academic Article GET IT
Times cited: 114
Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. Human gene therapy. 2005 Academic Article GET IT
Times cited: 40
AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene therapy. 2005 Academic Article GET IT
Times cited: 62
Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders. Human gene therapy. 2005 Review GET IT
Times cited: 29
Feasibility of gene therapy for late neuronal ceroid lipofuscinosis. Archives of neurology. 2001 Review GET IT
Times cited: 25
Domain interactions in protein tyrosine kinase Csk. Biochemistry. 1999 Academic Article GET IT
Times cited: 61
Chemical approaches to the study of protein tyrosine kinases and their implications for mechanism and inhibitor design. Pharmacology & therapeutics. 1999 Review GET IT
Times cited: 19
Expressed protein ligation: a general method for protein engineering. Proceedings of the National Academy of Sciences of the United States of America. 1998 Academic Article GET IT
Times cited: 987
Peptide and protein phosphorylation by protein tyrosine kinase Csk: insights into specificity and mechanism. Biochemistry. 1998 Academic Article GET IT
Times cited: 80

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Rapid Noninvasive Whole-body Imaging of AAV Gene Transfer Vectors awarded by National Institute of Biomedical Imaging & Bioengineering Co-Investigator 2019 - 2024

more ...

less ...

Background

education and training

Ph.D., Brown University 1997
B.S., St. Stephens College, Delhi University (India) 1991

Contact

full name

Dolan Sondhi

primary email

dos2011@med.cornell.edu

VIVO Weill Cornell Medical College

Dolan Sondhi Professor of Research in Genetic Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email